
On May 8, 2020, the FDA granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company).
On May 8, 2020, the FDA granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company).
Here's the coronavirus-related news you should know from this week.
In episode 5 of Over the Counter, experts in technology and pharmacy highlight the major ways that telemedicine is rising to meet the COVID-19 pandemic.
A recent study found that the programs may result in cost savings to health systems and patients.
Enhanced pharmacy services such as home delivery, curbside services, and expanded personal patient outreach create opportunities to address social determinants of health during the pandemic.
In part 2 of our interview, Dr. Cheryl Wisseh, PharmD, MPH, zone 5 director, NPhA, dives into the forces that bring about racial disparities, and offers pharmacy and health system-centered solutions.
Sandoz is collaborating with Civica Rx to provide critical injectable generic medicines to hospitals to help reduce supply shortages.
Dr. Cheryl Wisseh, PharmD, zone 5 director of the National Pharmaceutical Association (NPhA) discusses the ways that the current pandemic is displaying and doubling down on long standing disparities in our health care system.
Here's the coronavirus-related news you should know from this week.
Episode 4 of Over the Counter tackles dual pandemics: COVID-19 and racism. Experts discuss the most pressing health care and pharmacy issues related to racial disparity and the current COVID-19 pandemic.
The annual survey hit on key health-system pharmacy insights related to formulary management, pharmacogenomics, and opioid stewardship, among others.
Drug Topics interviews Steve Mok, PharmD, BCPS, BCIDP, manager of pharmacy services and director of health outcomes and analytics fellowship at Wolters Kluwer, to break down the ways that artificial intelligence (AI) can mitigate challenges posed by the COVID-19 pandemic.
In episode 3 of Over the Counter, experts weigh in on remdesivir, a potential COVID-19 treatment.
Here's this week's roundup of the coronavirus-related news you should know.
A collaboration between APhA and PTCB will help provide pharmacy technician credentialing in immunization delivery.
A new computer algorithm might be the next step toward accurate prediction of adverse drug reactions.
Julie Ann Justo, infectious diseases clinical pharmacist and associate professor at the University of South Carolina College of Pharmacy, discusses the latest data from Gilead's trials for Remdesivir, a potential COVID-19 treatment.
In an open letter, Gilead Chairman and CEO Daniel O’Day announced the price of remdesivir treatment for COVID-19.
Today, pharmacists are banding together to “eliminate racism, discrimination, injustice, and the marginalization of individuals within the profession.”
Check out this week's most important coronavirus-related news.
Existing surveillance networks can track influenza-like illness and lead to improved assessments on impact, prevalence, and severity of COVID-19.
In the newest episode of Over the Counter, 3 experts on professional burnout discuss the factors at play, and the impact the COVID-19 pandemic may be having on rates of pharmacist burnout.
Julie Ann Justo, infectious diseases clinical pharmacist and associate professor at the University of South Carolina College of Pharmacy, discusses the latest data from Gilead's trials for Remdesivir, a potential COVID-19 treatment.
A new poll by Gallup and West Health found that a majority of Americans have expressed numerous health care system-related concerns, including rising costs of drugs, insurance premiums, and health care in response to COVID-19.
“Telehealth has kept the entire health care system afloat and has enabled patients to continue to receive care,” the American Telemedicine Association’s president said in a testimony.